Press release

Fribourg, 11 March 2026

Infracore SA publishes audited 2025 consolidated results and AGM proposals

Dr. Stephan Thaler and Céline Amaudruz will be proposed for election to the Board of Directors

Infracore SA («Infracore»), a leading Swiss healthcare real estate company, today publishes its audited consolidated results for the financial year 2025 and outlines the proposals to be submitted to the Annual General Meeting («AGM») to be held on 25 March 2026, including the proposal to elect two new independent members to the Board of Directors.

In 2025, Infracore generated rental income of CHF 66.1 million and total revenue including revaluation gains of CHF 82.5 million. The Group recorded EBITDA of CHF 76.7 million, corresponding to an EBITDA margin of 93.0% of total revenue including revaluation. Profit for the period amounted to CHF 55.8 million, representing 67.6% of total revenue including revaluation.

At year-end, the market value of investment properties (including properties under construction and development projects) stood at CHF 1.412 billion, reflecting the continued strengthening of the portfolio. The portfolio is valued by the independent appraiser Wüest Partner AG, using the discounted cash flow (DCF) method.

Infracore’s portfolio continues to stand out for its exceptionally high occupancy: the investment portfolio achieved an occupancy rate of 98.7% in 2025, implying a very low vacancy rate of approximately 1.3%. 

Infracore also highlights its recurring cash-generation capacity: cash flow from operating activities before changes in working capital amounted to CHF 42.2 million (a commonly used proxy for Funds From Operations, “FFO”), representing 51.2% of total revenue including revaluation.

In terms of balance sheet strength, shareholders’ equity amounted to CHF 688.7 million. In addition, Infracore reports a conservative leverage profile. Net debt amounted to CHF 627.8 million. Relative to the market value of the property portfolio of CHF 1.412 billion, this corresponds to a Net Loan-to-Value (Net LTV) of 44.5%.  

Based on these results, the Board of Directors will propose to the AGM a dividend corresponding to a payout ratio of 95% of Infracore’s profit excluding result from revaluation.

Infracore also announces a strengthening of its Board’s independent representation, planning to have a majority of independent Board members. Two new independent candidates — Dr. Stephan Thaler and Céline Amaudruz — will be proposed for election to the Board of Directors at the AGM. Subject to their election, the Board will comprise three independent members, including Chairman Martin Gafner, alongside Dr. Stephan Thaler and Céline Amaudruz, in addition to one representative of Medical Properties Trust, Inc., Edward K. Aldag, and one representative of AEVIS VICTORIA SA, Antoine Hubert. The five board members with varied backgrounds, expertise and perspectives, whereof a majority is independent, align with best practice corporate governance. 

Infracore sees growing demand for efficient capital allocation and modern infrastructure solutions among public and private healthcare institutions. As Switzerland’s leading hospital real estate specialist and development partner, Infracore is well positioned to expand its sale-and-leaseback activities, leveraging its know-how in structuring long-term partnerships with hospitals.

The consolidated financial statements have been prepared in accordance with Swiss GAAP FER and were authorized for issue by the Board of Directors on 18 February 2026.  The statutory auditor concludes that the consolidated financial statements present a true and fair view in accordance with Swiss GAAP FER and comply with Swiss law. 

For more information:  Media and investor relations: c/o Dynamics Group, Zurich
Alexandre Müller, amu@dynamicsgroup.ch, +41 79 635 64 13

About Infracore SA
Infracore SA is a Swiss healthcare real estate company that owns, develops and manages hospital and clinic properties under long-term leases. Headquartered in Fribourg, the Group’s portfolio comprises 47 properties across 19 prime locations in Switzerland, totaling 221’157 sqm and a market value of CHF 1.41 billion. The assets are almost fully let under long-duration, inflation-indexed leases, predominantly to entities of Swiss Medical Network. Infracore generates recurring income from its stabilized portfolio and pursues growth through campus optimizations, extensions and selective developments, supported by a pipeline of about 42’053 sqm development potential. Infracore is jointly controlled by Medical Properties Trust, Inc. and AEVIS VICTORIA SA. www.infracore.ch.

About Medical Properties Trust, Inc.
Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities. From its inception in Birmingham, Alabama, the Company has grown to become one of the world’s largest owners of hospital real estate with 384 facilities and approximately 39,000 licensed beds in nine countries and across three continents as of December 31, 2025. MPT’s financing model facilitates acquisitions and recapitalizations and allows operators of hospitals to unlock the value of their real estate assets to fund facility improvements, technology upgrades and other investments in operations. www.medicalpropertiestrust.com.

About AEVIS VICTORIA SA
AEVIS VICTORIA SA invests in healthcare, hospitality & lifestyle and infrastructure. AEVIS′s main shareholdings are Swiss Medical Network Holding SA (76.3%, directly and indirectly), the only Swiss private network of hospitals present in the country’s three main language regions, MRH Switzerland AG, a luxury hotel group managing eleven hotels in Switzerland and abroad, Infracore SA (30%, directly and indirectly), a real estate company dedicated to healthcare-related infrastructure, Swiss Hotel Properties SA, a hospitality real estate division, and NESCENS SA, a brand dedicated to better aging. AEVIS is listed on the Swiss Reporting Standard of the SIX Swiss Exchange (AEVS.SW). www.aevis.com.

Biography of the proposed new Board Members
Céline Amaudruz is a Swiss citizen born in 1979. Subject to her election, she will be an independent member of the Board of Directors within the meaning of the Swiss Code of Best Practice. She holds a M.A. in Law from the University of Geneva. She currently serves as managing director and relationship manager at Reyl Intesa Sanpaolo. She is president and board member of various companies and foundations, including President of Groupe Minoteries SA, board member of Genève Aéroport and former president of TP Publicité SA. She previously served as Senior Expert Business Development and Head of Sustainability at Hirslanden AG. Céline Amaudruz has been vice-president of the Swiss People’s Party (SVP) since 2016 and a member of the Swiss National Council since 2011. She is an experienced leader with extensive experience in management and business development across public and private sectors. 

Dr. Stephan P. Thaler is a Swiss citizen born in 1962. Subject to his election, he will be an independent member of the Board of Directors within the meaning of the Swiss Code of Best Practice. He holds a PhD in Business Economics and is a Certified Board Member (HSG). Dr. Stephan P. Thaler currently serves as senior advisor (since 2025) and former CEO (until 2025) of Swiss Life Investment Foundation, where he was responsible for a real estate portfolio of CHF 9 billion. He served as chair of the Real Estate Investment Committee of Swiss Life Investment Foundation. His prior board and committee experience includes positions as independent board member and audit committee member of leading FINMA-regulated banks, including American Express Bank SA, Standard Chartered Bank (Switzerland) and Habib Bank Zurich. He also has board member experience in the health insurance and IT sectors serving as chair of the board of Taggeldkasse für Schweizerische Bildende Künstler and as board member of aXenta. Dr. Stephan P. Thaler is an executive and leader with extensive experience in the areas of real estate, institutional asset and risk management, and governance.

Gerresheimer AG: Publication of the 2025 annual and consolidated financial statements only after March 31, 2026, exclusion from the SDAX, postponement of the Annual General Meeting

Duesseldorf, March 10, 2026. Following today’s consultation with its auditor, Gerresheimer AG (ISIN: DE000A0LD6E6, “Gerresheimer”) has concluded that the audited annual and consolidated financial statements for the 2025 financial year will not be published by March 31, 2026, but later.

The preparation of the 2025 annual and consolidated financial statements is delayed because the ongoing investigations by a second external auditing firm into business transactions in financial years 2024 and 2025 and the preparation of the documents required for the audit are taking longer than expected. The Management Board aims to publish the audited annual and consolidated financial statements for the 2025 financial year in June 2026.

The delay in the publication of the 2025 annual and consolidated financial statements is expected to result in the exclusion of Gerresheimer shares from the SDAX index of Deutsche Börse AG.

As a result of the later publication of the 2025 annual and consolidated financial statements, the publication of the Quarterly Statement for the first quarter of 2026, which was announced for April 16, 2026, will also be postponed. The Company will announce a new date as soon as possible.

As a result of the later disclosure of the audited annual and consolidated financial statements, the Company’s Annual General Meeting cannot take place on June 3, 2026, as originally scheduled. The Company will announce a new date as soon as possible.

The Company has entered into discussions with its creditors to agree on an extension of the submission requirements for the audited annual and consolidated financial statements for the 2025 financial year as specified in the financing agreements.

_______________________

End of inside information
 

Contact Gerresheimer AG

Investor Relations

Guido Pickert
Vice President Investor Relations

T +49 211 6181 220
gerresheimer.ir@gerresheimer.com

Media

Jutta Lorberg
Head of Corporate Communication
T +49 211 6181 264

jutta.lorberg@gerresheimer.com

Immunic Announces Grant of Key European Patent
Protecting Relevant Dosing Regimens for Vidofludimus Calcium 

– Patent Covers Label-Mandated Dosing Scheme Across All Indications, Including Multiple Sclerosis; Previously Granted by the USPTO in 2023 –

– Broad Protection Extends to All Forms of Vidofludimus, Including Its Salts, Solvates and Free Acid –

– Multi-Layered Intellectual Property Strategy Expected to Provide Protection at Least Into 2041 in the United States and Into 2039 in Europe –

NEW YORK, March 10, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that the European Patent Office (EPO) has granted a key European patent, EP3713554, directed to label-relevant dosing regimens of lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838). The patent is expected to provide protection for vidofludimus calcium in Europe into 2038, and may be eligible for a Supplementary Protection Certificate (SPC), which could extend market exclusivity potentially into 2043. This patent was previously granted by the United States Patent and Trademark Office (USPTO) in 2023.

The claims broadly protect vidofludimus and its salt, solvate and free acid forms, in all label-relevant dosing regimens. This protection extends beyond a specific salt form, meaning that even alternative salts or forms will fall within the scope of the patent if used according to the label.

“Receiving this key patent in Europe represents a highly important advancement in our global intellectual property strategy for vidofludimus calcium and further reinforces the durability of our exclusivity position,” stated Daniel Vitt, Ph.D., Chief Executive Officer of Immunic. “This patent creates a particularly robust layer of protection that is difficult to design around, independent of indication or formulation. Together with our existing composition-of-matter, indication, method-of-treatment, dosing, process of production and formulation patents, this European patent significantly strengthens the multi-layered protection we have built around vidofludimus calcium. We will continue to expand this portfolio with the goal of maximizing long-term exclusivity following potential regulatory approval.”

Vidofludimus calcium is protected by several layers of granted patents in the United States, Europe and other jurisdictions around the world. These patents are directed towards composition-of-matter for forms of vidofludimus calcium; the treatment of relapsing-remitting multiple sclerosis with a specific dose strength used in the clinical trials; the treatment of progressive multiple sclerosis with specific dose strengths used in the clinical trials; the dosing regimens, including those used in clinical trials for the treatment of multiple sclerosis, as well as composition-of-matter of a specific polymorph of vidofludimus calcium and a related method of production of the material. In the United States, these patents provide protection into 2041, unless extended further. In addition, pending applications are directed towards the use of vidofludimus calcium and other salt forms as well as free acid forms for treating neurodegenerative diseases, which, if granted, could provide protection up to 2044, unless extended further, and the pharmaceutical product (formulation, production process and impurity profile), which, if granted, could provide protection up to 2045, unless extended further. Further undisclosed patent applications dedicated to strengthening the exclusivity period are currently in process. In addition to patent exclusivity, vidofludimus calcium, as a new chemical entity, is expected to benefit from regulatory data protection.

About Vidofludimus Calcium (IMU-838)

Vidofludimus calcium is an orally administered investigational small molecule drug being developed for chronic inflammatory and autoimmune diseases, currently in late-stage clinical trials for multiple sclerosis (MS). Vidofludimus calcium’s unique mode of action combines neuroprotective, anti-inflammatory and anti-viral effects to target the complex pathophysiology of MS. As a selective immune modulator, it activates the neuroprotective transcription factor, nuclear receptor-related 1 (Nurr1), which provides direct and indirect neuroprotective effects. Additionally, vidofludimus calcium achieves anti-inflammatory and anti-viral effects through highly selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). Vidofludimus calcium is currently being evaluated in phase 3 clinical trials for the treatment of relapsing MS. In a phase 2 clinical trial, it showed therapeutic activity in relapsing-remitting MS patients, significantly reducing brain lesions and demonstrating encouraging results in reducing confirmed disability worsening. Additionally, vidofludimus calcium demonstrated clinical benefits in progressive MS patients by showing substantial reductions in confirmed disability progression and statistically significant confirmed disability improvement in a phase 2 clinical trial. To date, vidofludimus calcium has been exposed to more than 3,400 individuals and has shown an attractive pharmacokinetic, safety and tolerability profile. Vidofludimus calcium is not yet licensed or approved in any country.

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. The company’s lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases such as celiac disease, inflammatory bowel disease, and graft-versus-host disease. IMU-381 comprises next-generation molecules in preclinical testing for neurologic, gastrointestinal and other autoimmune diseases leveraging the company’s Nurr1 platform. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic’s development programs and the targeted diseases; the potential for vidofludimus calcium to safely and effectively target diseases; preclinical and clinical data for vidofludimus calcium; the feasibility of advancing vidofludimus calcium to a confirmatory phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials, anticipated clinical milestones and regulatory approvals; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, and the ability to raise sufficient capital to continue as a going concern, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com

US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com

NOT TO BE TRANSMITTED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, TO OR WITHIN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTIONS IN WHICH SUCH TRANSMISSION OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE REFER TO THE IMPORTANT NOTES AT THE END OF THIS AD-HOC NOTIFICATION.

Publication of inside information pursuant to Article 17 (1) of Regulation (EU) 596/2014 on market abuse (Market Abuse Regulation – MAR)

Dermapharm Holding SE resolves public share buyback offer for up to 4,300,000 shares

Grünwald, Germany, 10 March 2026 – The Management Board of Dermapharm Holding SE (the “Company“) (ISIN DE000A2GS5D8 / WKN A2GS5D) resolved today, with the approval of the Supervisory Board of the Company and on the basis of the authorization granted by the Annual General Meeting of the Company on 14 June 2023, to make a public share buyback offer to the shareholders of Dermapharm Holding SE for a total of up to 4,300,000 shares (representing approximately 7.99% of the share capital of the Company) at an offer price of EUR 42.00 per share. The repurchased shares are intended to be cancelled.

The acceptance period commences on 11 March 2026 at 00:00 hours (CET) and ends, subject to an extension by the Company, on 24 March 2026 at 24:00 hours (CET). If more than 4,300,000 shares are tendered for repurchase into the offer, acceptances will be taken into account on a pro-rata basis in the ratio of 4,300,000 shares to the total number of shares tendered for repurchase by the shareholders. Further details of the public share buyback offer are included in the offer document, which will be published on the website of Dermapharm Holding SE (https://ir.dermapharm.de) under the heading “Investor Relations – Share – Share Buyback – 2026” and, thereafter, in the Federal Gazette (Bundesanzeiger) at www.bundesanzeiger.de.

Contact

Investor Relations & Corporate Communications
Britta Hamberger
Tel.: +49 (0)89 – 64186-233
E-mail: ir@dermapharm.com

Disclaimer

This notification may not be published, distributed or transmitted in the United States of America, Canada, Australia or Japan. This notification is not directed at, or intended to be transmitted to or used by, any person who is a national or resident of, or located in, any state, country or other jurisdiction where the transmission, publication, use or making available of this notification would violate applicable law or would require a registration or license within such jurisdiction.

Neither this notification nor its content may be published, sent, distributed or disseminated in the United States of America by use of any postal service or by any other means or instrument of interstate commerce or of foreign trade or of the facilities of any national stock exchange of the United States of America. This includes, but is not limited to, fax transmission, electronic mail, telex, telephone and the Internet. Copies of this notification and other related documents may not be sent or transmitted to or within the United States of America either.

This notification does not constitute an offer for the purchase of securities, or a solicitation to make an offer for the purchase of securities, of the Company in the United States of America, Germany or any other jurisdiction.

This notification contains forward-looking statements. These statements are based on the current views, expectations and assumptions of Dermapharm Holding SE’s management and entail known and unknown risks and uncertainties that may cause the actual results, performance or events to differ materially from those expressed or implied by the forward-looking statements. The actual results, performance or events may differ materially from those described therein due to, among other things, changes in the general economic environment or competitive situation, risks associated with capital markets, foreign exchange rate fluctuations and competition from other companies, changes in a foreign or domestic legal system, particularly with respect to the tax environment, or other factors. Dermapharm Holding SE assumes no obligation to update forward-looking statements.

Hamburg, Germany, March 10, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced ‘Horizon’, the next phase in its multi-stage transformation initiative. Horizon advances the company’s evolution by implementing a new and focused operating model built across the three pillars of operations, science and commercial execution. This model is designed to generate above market growth and enhance operating leverage in an environment of normalized demand and increased expectations on scientific and operational performance, building on the Priority Reset in 2024 and the articulation of strategic levers for mid-term value creation in 2025.

Horizon will simplify organizational structures, reorganize Evotec’s global expertise into new, focused Centers of Excellence and align the company footprint to support more disciplined execution in high-value segments of the drug discovery and preclinical development market.

Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:

“Horizon represents the next step in Evotec’s structured transformation to position the company for sustainable, high-quality growth. Following the disciplined cost actions implemented over the past two years and the strategic priorities we set in 2025, we are now transforming our operating model. This will enable deeper integration, faster decision making and greater agility for our customers and partners. Horizon positions Evotec for stronger performance through 2027 and lays the foundation for further optimization and intelligent scaling toward 2030.”

Strategic Rationale

Horizon marks an important step to position Evotec for the next phase in the evolution of the global drug discovery and pre-clinical development market, driven by deeper scientific excellence and advances in data science, automation and AI. It represents a building phase after which the company will operate with a more disciplined cost base, a higher-value technology-driven revenue mix, improved operating margins and a platform capable of delivering sustainable and profitable growth. Operational streamlining will increase agility and responsiveness and will enable faster execution, particularly within Evotec’s drug and preclinical development (D&PD) business.

Horizon accelerates delivery on Evotec’s four strategic levers for mid-term value creation:

1. Above market growth rates at better-quality earnings
2. Commitment to operational excellence
3. Better monetization of technology and assets of Just – Evotec Biologics
4. Upside through returns on partnered asset pipeline

Implementation Plan

As part of the transformation, Evotec plans to further optimize its global footprint, reduced from 19 to 14 sites between 2024 and 2025, to 10 sites over the next two years. The footprint optimization will be accompanied by a workforce adjustment affecting up to 800 positions across all locations. Centers of Excellence will enable a centralized innovation infrastructure by concentrating key areas of expertise. This focused model is designed to strengthen scientific depth, enhance cross-disciplinary collaboration and support growth in high-value therapeutic and technology-driven areas.

Implementation of these measures has been initiated, with first operational effects anticipated in the second half of 2026. Horizon is expected to be substantially implemented by the end of 2027, taking into account phased workforce adjustments in accordance with local legal requirements. The organizational changes and associated charges that Evotec expects to incur are subject to a number of assumptions, including local legal requirements. The company is committed to a transparent process and does not expect material disruption to ongoing customer programs.

Paul Hitchin, Chief Financial Officer of Evotec, said:

“From a financial perspective, Horizon represents a fundamental realignment of our operating model and cost structure. We are simplifying our cost base, reallocating resources toward higher-value, intellectual property-driven programs and improving operating leverage across the business to create value for our stakeholders. While 2026 will be a transition year, our objective is a structurally more focused organization with enhanced long-term profitability and strengthened cash generation through 2027 and beyond.”

Financial Framework and Medium-Term Outlook

Considering the start of Horizon and the transition year expected in 2026, Evotec is revising its medium-term financial framework to reflect a phased trajectory from 2026 through 2030.

The revised framework incorporates the timing of restructuring measures and the continued development of the revenue mix across Evotec’s two business segments.

Preliminary FY 2025 Performance (Unaudited)

To provide transparency as part of the updated framework, Evotec is sharing preliminary, unaudited full-year 2025 financial figures, subject to completion of year-end closing and audit procedures.

For full-year 2025, Evotec expects results to fall within its previously communicated guidance ranges:

• Group revenues of approximately €788 million at the high end of the €760-800 million guidance (€811 million at constant exchange rates (CER))
• Adjusted Group EBITDA of approximately €41 million versus guidance of €30-50 million
  (€52 million CER)

Evotec will report final fourth quarter and full-year 2025 results on April 8, 2026.

Discovery & Preclinical Development (D&PD)

Preliminary unaudited revenues for the D&PD segment are expected to amount to approximately €529 million (€540 million CER), representing a year-on-year decrease of 13 %. Adjusted EBITDA for the segment is expected to amount to approximately -€12 million (-€5 million CER).

Just – Evotec Biologics (JEB)

Preliminary unaudited revenues for the JEB segment are expected to amount to approximately €259 million (€271 million CER), representing a year-on-year increase of 40 %. Adjusted EBITDA contribution from JEB is expected to amount to approximately €53 million (€57 million CER).

Horizon Financial Impact and 2026 Guidance

Horizon is expected to be substantially completed by the end of 2027. 2026 will represent a transition year, with meaningful operational improvements anticipated to become increasingly visible in the second half.

Evotec expects total run-rate cost savings of approximately €75 million from the structural Horizon measures by the end of 2027 of which a positive contribution will be already realized in 2026.

To implement Horizon, Evotec expects total cash restructuring charges of approximately €100 million over the 2026–2028 period. There are also expected to be non-cash components related to asset impairments.

Evotec enters 2026 with annualized savings of approximately €60 million realized in 2025, fully embedded in its structurally lower operating cost and driven by improved capital discipline and a progressively more technology-driven revenue mix and base. These structural cost reductions, combined with improved utilization and a shift toward higher-margin technology and platform-based activities, are expected to enhance operating leverage and support sustained margin expansion from 2027 onward.

For full-year 2026, Evotec expects:

• Group revenues of approximately €700-780 million (€730-810 million CER)
• Adjusted Group EBITDA of approximately €0-40 million (€10-50 million CER)

Medium-Term Framework 2026–2030

Evotec is providing a new medium-term framework for 2026-2030 to consider the timing and impact of Horizon while maintaining its growth ambition. The framework reflects a phased trajectory.

• Group revenues are expected to grow to > €1 billion (8-12 % CAGR)

• Adjusted EBITDA margin is expected to reach 20% by 2028 and exceed that level by 2030

The framework reflects:

• Anticipated recovery of the early drug discovery and development market
• Cost reductions from Horizon with positive contributions beginning in 2026
• Continued shift toward higher-margin, technology-enabled, capital-efficient revenue streams
• Continued CAPEX-lighter approach to below 10 % of revenues
• Operating leverage as growth resumes following the 2026 transition year

This phased approach defines a clear trajectory from operational reset, through transition, to sustainable margin expansion and scalable growth by 2030. Further details on the medium-term framework will be provided during the final fourth quarter and full-year 2025 reporting on April 8, 2026.

Webcast Details

Evotec will host a webcast and conference call today at 3 p.m. CET / 2 p.m. GMT / 10 a.m. EDT.

To join the audio webcast and to access the presentation slides, please register via this link.

The on-demand replay of the webcast will be available under the same link after the event and on
our website.

Conference Call Details

To join the conference call, please pre-register via this link. You will receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.
A simultaneous slide presentation for participants dialing in via phone is available under this link.

About Evotec SE

Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision.Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

Forward-looking statements

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Investor Relations and Media Contact

Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com

Dermapharm Holding SE records decline in consolidated revenue, adjusted consolidated EBITDA improves

• In 2025, consolidated revenue decreases to EUR 1,165.0 million (-1.3%) following phase-out of low-margin products in “Parallel import business” segment
• Adjusted EBITDA increases by 2.9% to EUR 324.8 million; adjusted EBITDA margin at 27.9% (up 1.2 percentage points year on year)
• Unadjusted EBITDA rises by 2.8% to EUR 317.6 million, margin improves by 1.1 percentage points to 27.3%
• Earnings and margin development remains heavily dependent on structural measures

Grünwald, 10 March 2026 – Dermapharm Holding SE (“Dermapharm”), an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today published its unaudited preliminary consolidated figures (IFRS) for the 2025 financial year.

Consolidated revenue decreased to EUR 1,165.0 million in the reporting period (previous year: EUR 1,180.8 million). The 1.3% decline was due primarily to portfolio adjustments in the Parallel import business in the wake of the systematic phase-out of low-margin products. The organic growth in the “Branded pharmaceuticals” segment did not fully offset this decline.

Adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) rose by 2.9% to EUR 324.8 million (previous year: EUR 315.6 million), with the adjusted EBITDA margin amounting to 27.9% (previous year: 26.7%). Prior to adjustment, EBITDA increased by 2.8% to EUR 317.6 million (previous year: EUR 308.9 million). The EBITDA margin thus improved from 26.2% in the previous year to 27.3%.

“In 2025, we once again increased our earnings year on year. The systematic focus of our portfolio and the robust development of our core segments underscore the stability and profitability of our Company,” said Dr Hans-Georg Feldmeier, CEO of Dermapharm Holding SE.
 

Branded pharmaceuticals

The segment recorded growth in revenue as well as EBITDA. Organic growth remains solid on the back of a broadly diversified product portfolio. The acquisition of the Austrian pharmaceuticals company F. Trenka expands the Company’s international footprint in the MENA region.

Other healthcare products

The segment’s revenue trend in the reporting year remained on par with the prior-year level. Growth at Euromed and Anton Hübner did not fully offset the decline at Arkopharma. Currency-related effects resulting from the depreciation of the US dollar also weighed on earnings.

Parallel import business

In financial year 2025, Dermapharm continued to restructure its product portfolio with the aim of increasing its focus on high-margin products. Lucrative but low-margin products were gradually phased out. This restructuring led to a significant decline in revenue and earnings.

IFRS figures for 2025 and the previous year

 * 2025 EBITDA was adjusted for non-recurring items amounting to EUR 7.2 million.
   2024 EBITDA was adjusted for non-recurring items amounting to EUR 6.7 million.

Company profile:

Dermapharm – Pharmaceutical Excellence “Made in Europe”

Dermapharm is an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products. Founded in 1991, the Company is based in Grünwald near Munich. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations, including in Germany, the rest of Europe and the United States.

In the “Branded pharmaceuticals” segment, Dermapharm has more than 1,400 marketing authorisations with more than 400 active pharmaceutical ingredients. Dermapharm’s portfolio of pharmaceuticals is tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany. The Company’s integrated business model extends from in-house product development and production through quality management and logistics to the distribution of branded pharmaceuticals by a trained pharmaceutical sales force.

Dermapharm bundles food supplements, herbal pharmaceuticals, cosmetics, medical devices, herbal extracts and medicinal cannabis in its “Other healthcare products” segment. In this segment, Dermapharm can tap the expertise of Arkopharma, the market leader for phytotherapeutic food supplements in France, and the Spanish company Euromed S.A., a leading global manufacturer of herbal extracts and plant-based active ingredients for the pharmaceuticals, nutraceuticals, foodstuffs and cosmetics industries.

Dermapharm also operates the “Parallel import business” segment under the axicorp brand. axicorp imports originator pharmaceuticals from other EU Member States and resells them to pharmaceuticals wholesalers and pharmacies in Germany. This enables axicorp to benefit from the different pricing structures in the individual EU member states. Based on revenue, axicorp is currently the seventh largest parallel importer in Germany.

With a consistent R&D strategy and numerous successful product and company acquisitions and by stepping up its internationalisation efforts, the Group is continuously optimising its business activities and seeks external growth opportunities in addition to organic growth.

Contact

Investor Relations & Corporate Communications
Britta Hamberger
Tel.: +49 (0)89 – 64186-233
E-mail: ir@dermapharm.com